Physician profile
James Bown
NPI 1629081260
$4,406.69
in general payments reported to CMS, 2019-2025
31 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $269 · 2021: $617 · 2022: $732 · 2023: $824 · 2024: $860 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,306 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,306.27 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,548.61 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $505.47 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $415.95 | 2019-2025 | Entyvio, Gattex |
| Genzyme Corporation | $278.56 | 2022-2025 | |
| Pfizer INC. | $172.37 | 2019-2025 | |
| Celgene Corporation | $138.27 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $132.93 | 2019-2025 | General - Polypectomy |
| Qol Medical, LLC | $128.62 | 2019-2025 | Sucraid |
| Nestle Healthcare Nutrition INC. | $121.72 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $113.31 | 2020-2025 | |
| Madrigal Pharmaceuticals | $105.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $84.91 | 2021-2022 | |
| Gilead Sciences, INC. | $76.60 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $68.98 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.43 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $54.36 | 2023 | |
| Daiichi Sankyo INC. | $45.70 | 2019-2023 | Injectafer |
| Allergan, INC. | $44.60 | 2019 | |
| Organon LLC | $42.42 | 2023-2024 | Renflexis |
| Shire North American Group INC | $35.02 | 2019 | |
| Ironwood Pharmaceuticals, INC | $34.96 | 2020 | |
| Braintree Laboratories, INC. | $34.67 | 2019 | |
| Phathom Pharmaceuticals, INC. | $32.67 | 2024 | Voquezna |
| Orphalan INC | $28.78 | 2025 | Cuvrior |
| Aimmune Therapeutics, INC. | $22.36 | 2024 | |
| Ardelyx, INC. | $17.98 | 2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $17.29 | 2025 | Iqirvo |
| Ucb, INC. | $16.63 | 2019 | |
| Alfasigma USA, INC. | $14.54 | 2020 | |
| Amgen INC. | $12.74 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,973.95 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.